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1. Introduction 
Immunosuppression is a condition characterized by immune dysfunction at either cellular 
or humoral levels [1]. Defective cellular levels include alterations in neutrophils, 
monocyte/macrophage, and natural killer (NK) cells for innate immunity or alterations in B 
or T lymphocytes for adaptive immunity [2, 3]. In contrast, immune dysfunction at the 
humoral level is largely due to alteration in soluble factors mediated by complement or 
chemokines for innate immunity [4] or due to alteration in antibodies or cytokines for 
adaptive immunity [5]. Most of these alterations are congenital in nature as evidenced in 
patients with primary immunodeficiency diseases. The defective compartment of the 
immune system determines the proclivity of the invading pathogens and the contracted 
infection is usually disseminating. Consequently, the inflicted immunosuppression is 
permanent unless reconstituted by immunoglobulin transfusions or bone marrow 
transplantation.  On the other hand, secondary immunosuppression may be internal as a 
consequence of excessive adenosine release [6] into the extracellular space as evidenced in 
multiple organ failure (e.g. pancreas, kidney, liver) or it might be externally induced by a 
number of causal agents including infectious pathogens, immunosuppressive drugs, 
antimicrobial drugs, and anti-neoplastic drugs. The causal, pathophysiology, and methods 
used to evaluate immunosuppression due to pathogens are the focus of this chapter. 
2. Immunosuppression induced by primary infections  
Acquired immunosuppression due to pathogens is primarily caused by viruses that invade 
the cellular compartment of the immune system. The condition is seen in limited population 
of both humans and animals. In humans, it is caused by pathogens that selectively infect 
lymphocytes such as infection of T cells with human immunodeficiency virus (HIV) types I 
& II [7], or infection with human T-cell lymphotropic virus types I & II [8-10]. Human B 
lymphocytes, on the other hand, are prone to infection with Epstein-Barr virus (EBV) [11]. In 
animals, however, direct infection of immune cells that lead to immunosuppression is seen 
in cats infected with feline leukemia virus (FeLV) [12], cattle infected with bovine leukemia 
virus (BLV) [13] or in chickens infected with Marek’s disease virus (MDV) [14] or infectious 
www.intechopen.com
 
Immunosuppression – Role in Health and Diseases 
 
216 
bursal disease (IBD) [15] virus.  The striking feature in all of these infections is that 
immunosuppression is latently developed following viral replication that leads to 
lymphocytes depletion. Consequently the inflicted host develops immune anergy with 
increased susceptibility to opportunistic infections.  Summary of the causal agents and the 
target cells involved in the induction of immunosuppression are presented in Table 1. 
 
 
HIV= human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome; IRIS= immune 
reconstitution inflammatory syndrome; HAART= highly active antiretroviral therapy; HTLV= human 
T-cell lymphotropic virus; ATL= adult T-cell leukemia; HAM/TSP=HTLV-1-associated myelopathy/ 
tropical spastic paraparesis; EBV= Epstein-Barr virus; IMN= infectious mononucleosis; BL= Burkitt’s 
lymphoma; HD= Hodgkin’s disease; XLL= X-linked lymphoproliferative syndrome; OHL= oral hairy 
leukoplakia; FeLV= feline leukemia virus; BLV= bovine leukemia virus; LS= Lymphosarcoma;  
MDV= Marek’s disease virus; IBDV= infectious bursal disease virus; IBD= infectious bursal disease 
Table 1. Common lymphotropic infections associated with immunosuppression 
             
Causal agent  Host        Immune target cells     Disease  Immunologic sequelae 
             
HIV-1&2 Humans       CD4+ T-cell                AIDS      - CD4 cells depletion; 
     - Immune dysfunction;  
   -IRIS after treatment with HAART 
HTLV-1         Humans       CD4+ T-cell       ATL;          ↑ IFN-γ; ↑ TNF-α.   
            HAM/TSP  
HTLV-2        Humans       CD8+ T-cell              Neuropathy          Immunosuppression    
EBV           Humans       B cells      IMN; BL;             Immunosuppression  
    HD; XLL; OHL 
FeLV          Cats            CD4+ T-cell   Leukemia  Immunosuppression 
BLV          Cattle           B cells    Leukemia; LS Immunosuppression 
        
MDV          Chickens      CD4+ T-cell  Marek’s disease         Immunosuppression 
        Marek’s lymphoma        
IBDV          Chickens      B cells         IBD                          Immunosuppression 
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i. HIV infection: In HIV infection, immune dysfunction is likely due to combinatorial 
effects resulting from infection of immune cells (CD4+ T cells, macrophages, dendritic 
cells) with HIV, uncontrolled viral replication that impairs antigen presentation, 
increased mutations in env protein gp120 that leads to virus tropism and survival, 
increased activation of T helper cells by alloantigens, increased apoptosis by activated 
CD4+ T helper cells, down-regulation of CD4+ synthesis with functional impairment, 
and perturbation of cytokine pathways [7,16-19].  These immunologic defects can be 
partially restored in HIV patients treated with highly active antiretroviral therapy 
(HAART) [20].  Despite a reduced viral load and improved CD4+ T cells count, a 
paradoxical response known as immune reconstitution inflammatory syndrome (IRIS) 
has been evolved in HIV patients treated with HAART [21-23]. The induction of IRIS is 
worsened in HIV patients with preexisting opportunistic infections [24]. In essence, the 
severity of IRIS depends on CD4+ T cells count (≤ 100-200 cells/µl), degree of 
lymphocyte apoptosis or proliferation, and the degree of viral suppression and immune 
recovery after the initiation of treatment with HAART. All of these factors constitute a 
challenge to HIV vaccine development [25]. In animals, however, paradoxical 
immunosuppression associated with IRIS is rarely encountered due to the short life 
span of infected animals and variations in the care and management of sick animals 
compared to humans.  
ii. HTLV infection: In HTLV infection, the virus preferentially infects CD4+ T cells and 
causes their transformation into malignant lymphoma in vitro.  The majority of HTLV- 
infected patients are asymptomatic and few are carriers that may develop a chronic 
illness through time. The virus has 2 unique genes, tax and rex, in addition to the 
standard retroviral genes (gag, pol, and env) that play a central role in lymphocytes 
transformation. The HTLV-1 tax gene product is known to stimulate viral mRNA 
synthesis, interleukin (IL)-2 production, and IL-2 receptor (R) expression which are key 
elements for lymphocytes proliferation and transformation into malignant cells [9, 10]. 
The aberrant changes in T cells function during the transformation process may 
contribute to immunosuppression. However, in some patients, the humoral antibody 
response to HTLV antigens may be detected in sera of infected patients indicating that 
HTLV may not be the primary causes of all T cell lymphomas.  In addition to T cell 
leukemia, some carriers of HTLV-1 may develop an inflammatory disease of the central 
nervous system called HTLV-1- associated myelopathy/tropical spastic paraparesis 
(HAM/TSP).  Patients with HAM/TSP have increased HTLV-1 provirus load and 
increased numbers of HTLV-1-specific cytotoxic T lymphocytes (CTL, CD8+ T cells) 
that were restricted to the HTLV-1 tax protein. However, the HTLV-1-specific CTL of 
these patients have been demonstrated to produce IFN-Ǆ and TNF-ǂ that promote 
inflammation.  Therefore, HTLV-1 tax-specific CTLs play a major role in the 
immunopathogenesis of HAM/TSP.  
iii. EBV infection: Primary EBV infection causes infectious mononucleosis, a self limiting 
and silent disease in most inflicted patients. The virus exclusively infects B cells than 
any other cell type and persisted within the carrier’s B cells to establish latent infection. 
In vitro EBV infection of human B lymphocytes has been demonstrated to induce B cell 
immortalization and proliferation [26]. The process carries the viral genome indefinitely 
and used for the generation of various lymphoblastoid cell lines. In addition to its B 
cells involvement, EBV infection has been demonstrated in epithelial cells of 
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nasopharyngeal carcinoma as well as in the epithelial layer of oral hairy leukoplakia 
(OHL), a benign exclusive lesion in HIV individuals [11]. Despite its various clinical 
manifestations and lymphoid cells activation, EBV infection is common in 
immunocompromised patients. The control of EBV infection has been attributed to 
CTL (CD8+ T cells) [27] and the consequent immunosuppression is multifactorial 
effect.  
iv. FeLV infection: Infection with FeLV is usually asymptomatic and is species-specific. 
Persistent infection emerges in carrier’s cats and correlated well with persistent viremia 
that last for months [12]. The virus infects primarily T lymphocytes and spread to other 
lymphoid tissues including bone marrow and glandular epithelium. This broad 
infection lead to the development of leukemia, lymphoma, and non-regenerative 
anemia in persistently infected cats.  Immunosuppression in pet cats showed 
suppressed antibody and T cell responses, prolonged allograft rejection times, thymic 
atrophy, and depletion of the paracortical zones in lymph nodes. 
v. BLV infection: BLV infects primarily B cells and persisted to induce their 
transformation into cancerous cells after long latent periods [13]. In addition to B cells 
infection, BLV infect cells of the monocyte/macrophage lineage. Infection is usually 
silent but may progress to persistent lymphocytosis and tumor production. 
Immunosuppression due to BLV is largely contributed by altered gene expression for 
the cytokines IL-2, IL-6, IL-10, and IL-12, increased B cells apoptosis, down-regulation 
of TNF-ǂ and its receptor, and alteration in cells signaling pathway. 
vi. MDV infection: The pathogenesis of MDV that leads to lymphoma development with 
consequent  immunosuppression [14] involves 4 stages: early cytolytic infection in 
which the virus spread from cell to cell and B cells were demonstrated as the primary 
targets for this stage; latent infection in which activated CD4+ T cells are the 
predominant targets in lymphoid organs as well as schwann cells of peripheral nerves 
and spinal ganglia; late cytolytic infection is characterized by permanent 
immunosuppression of T cells; and transformation stage in which T cells lymphoma 
develop with a dominant expression of Marek’s disease tumor-associated surface 
antigen (MATSA). The resultant immunosuppression caused by MDV infection is 
largely attributed to loss of effector cells in major lymphoid organs, the bursa of 
Fabricius and the thymus as well as in bone marrow tissues. Consequently, this 
cytolytic infection leads to the development of atrophy at the bursa and thymus as well 
as aplasia in bone marrow cells. Studies by Calnek demonstrated that the degree of 
immunosuppression may be related to the pathotype of MDV isolates. However, the 
contribution of host factors in this immunosuppression needs to be elucidated. 
vii. IBDV infection: Initial infection with IBDV involves lymphocytes and macrophages of 
gut- associated lymphoid tissues (GALT) followed by invasion of lymphoid follicles at 
the bursa of Fabricius, the primary source of B lymphocytes in avian species [15]. Since 
the bursa represents the primary target organ for viral replication, IgM positive B 
lymphocytes are the target cells for viral lysis. The consequent infection results in bursal 
atrophy and B cells depletion. Indeed, B cells depletion extends to other lymphoid 
tissues including the thymus, GALT, and the Harderian gland. Therefore, the 
production of antibodies will be impaired and the cellular immune response will be 
diminished in chickens infected with IBDV.  The inflicted damage to the bursal tissue 
coupled with B cells depletion, and loss of T cells function contribute to the 
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development of immunosuppression in chickens infected with IBDV. Restoration of 
immunity by adoptive transfer may be possible but no paradoxical inflammatory 
response has been demonstrated.  
3. Immunosuppression induced by bacterial infections  
It is well established that infection with some intracellular bacteria may have indirect effects 
on the immune system with consequent induction of immunosuppression.  Among the 
leading causal agents, Mycobacterium tuberculosis, Ehrlichia chaffeensis, Brucella melitensis, 
Coxiella burnetti, Bartonella Sp. and Nocardia farcinica. However, in immunocompromised 
patients, infections with mycobacterial species or agents of bacterial pneumonia are 
commonly observed in clinical practice. In AIDS patients, disseminated infections with 
Mycobacterium tuberculosis or Mycobacterium avium complex are prominent [7, 28].  In 
contrast, deadly infection with Nocardia farcinica [29] has been reported in an 
immunocompromised patient with type II diabetes and end-stage renal failure. Thus, 
infection with opportunistic pathogens may be more deleterious to the host than infection 
caused by pathogens that primarily induce immunosuppression.  In general, the underlying 
mechanism of immunosuppression due to bacteria varies according to the host-parasite 
cellular interactions, and the elicited host immune mediators that cause a shift in the balance 
between Th1 and Th2 responses. For instance, sustained production of transforming growth 
factor (TGF)-ǃ has been associated with immunosuppression in patients with chronic 
brucellosis [30] or tuberculosis [31]. Further, other mechanisms exist for pathogens induced 
immunosuppression and they are largely attributed to a defective interaction between the 
microbe (bacteria, viruses, fungi, or protozoan parasites) and cells of the immune system 
(macrophages, dendritic cells, lymphocytes, natural killer). Support for this notion stems 
from the ability of certain intracellular pathogens to prevent phagolysosome biogenesis, 
inhibition of cellular autophagy, and inhibition of antigen presentation [28, 32-35].  The 
prototype models for these mechanisms have been established by several investigators who 
studied the interaction of Mycobacterium tuberculosis with the macrophage [36]. In essence, 
the induced immnuosuppression is the target of several microbial virulence factors in an 
effort to establish a disease process at their predilection sites. Major virulence factors 
associated with bacterial infection include toxin production, polysaccharide or polypeptide 
capsule formation, and secretion of degradative enzymes that promote tissue invasiveness, 
proteineous pili and mucosal adhesins. Individuals with prolonged immunosuppression 
offer a rich environment for microbial growth, replication, and pathogencicity conduction. 
Consequently, the resulting disease will be much exacerbated due to microbial abundance 
and invasiveness secondary to shift in balance between proinflammatory and anti-
inflammatory factors of the host. Therefore, activation of the antimicrobial activity of 
leukocytes as well as induction of immune cytokines (interferon (IFN)-Ǆ, interleukin (IL)-12, 
IL-2 and tumor necrosis factor (TNF)-ǂ) are crucial elements in the restoration of cellular 
immunity [3] in patients with secondary immunosuppression due to bacteria.   
In general, the extent of microbial immunosuppression is dependent on the balance of 
proinflammatory and anti-inflammatory mediators following injury and/or infection, 
disease duration (acute, chronic), immunocompetence of the inflicted host, dosage rate and 
treatment regimen of anti-microbial drugs used, and a synergy of  these therapy, if exist. 
The balance between these factors had a major impact on the restoration of immunity 
and/or disease progression. 
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4. Immunosuppression induced by opportunistic viral infections 
In clinical practice, the most common opportunistic viral infections that were encountered in 
immnuocompromised patients include, cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
and human herpesvirus 8 (HHV8). In addition to their primary causes of disease in 
immunocompetent hosts, these viruses have been detected in blood and lesions of 
immnuocompromised patients with AIDS, renal and bone marrow transplants as well as in 
patients with neoplasms [24, 26, 37, 38]. Latency of infection is commonly encountered with 
these viruses while congenital infection is prominently seen in CMV. Therefore, newborns 
with immunological defects are at a highest risk of CMV disease. However, infection with 
HHV8 causes Kaposi’s sarcoma, the most common cancer in patients with AIDS. The 
inflicted immunosuppression due to these viral infections is usually dual in nature and 
largely attributed to inhibition of T cell responses. 
5. Immunosuppression induced by antimicrobial drugs  
Although most antimicrobial drugs are safe and effective in patients with infectious 
diseases, some are toxic to the host cells causing alterations in immune cells function that 
may lead to immunosuppression [39]. Major immunotoxic effects attributed to antimicrobial 
drugs include neutropenia and agranulocytosis, autoimmune diseases development, or 
hypersensitivity reactions. These toxic effects had influenced the therapeutic choice of some 
antimicrobial drugs despite their clinical interventions. The mechanistic events involved in 
the alteration of immune cells with consequent immunosuppression are not well 
established.  However, in clinical practice, the antiviral agents, Ganciclovir, Ribavirin, and 
Zidovudine as well as the antibacterial agents, Chloramphenicol, Rifampicin, Sulfa 
derivatives, Macrolides (Azithromycin, Clarithromycin, or Erythromycin) and ǃ-lactam 
(Penicillins, Cephalosporins) antibiotics are leading causes of neutropenia, agranulocytosis, 
inhibition of phagocyte function, and immunotoxic effects on bone marrow precursor cells. 
The latter effect is dose dependent and usually diagnosed by adding the patient’s serum and 
the antibiotic drug under investigation to an in vitro culture of bone marrow cells. However, 
in addition to toxic effects on immune cells, some antibacterial drugs or their metabolites 
have been implicated in allergic reactions as exemplified by the ß-lactam, Penicillin G. The 
sensitizing capacity of any antimicrobial drug depends solely on its ability to interact 
irreversibly with tissue proteins to form complexes that provoke immune effector cells. 
Consequently, an IgE-mediated allergic reaction would be induced and the competence of 
these patients to mount a specific immune response is paralyzed.  Other immunologic 
caveats attributed to antibacterial drugs include production of immune complexes as shown 
in drug-induced systemic lupus erythematosus with Isoniazid, Sulfonamides, Streptomycins, 
and Penicillins or cell-mediated hypersensitivity reactions as shown in contact dermatitis 
with Penicillins, Neomycins, and Nitrofurantoin. Again, the immunocompetence of patients 
with drug-induced autoimmune disorders or hypersensitivity reactions would be 
jeopardized unless reconstituted. In any event, alterations in immune cells caused by these 
drugs are expected to affect the immune function with consequent immunosuppression. At 
this stage, the host is more prone to infection with several opportunistic pathogens.  
In contrast, immunosuppression induced by immunosuppressant drugs had a profound 
effect on lymphocytes function [1]. Common drugs used for this purpose include 
Calcineurin inhibitors (Cyclosporine A or Tacrolimus), glucocorticoids, and Mycophenolate 
www.intechopen.com
 
Microbial Immunosuppression 
 
221 
mofetil.  The resultant immunosuppression induced by these drugs led the host to be more 
vulnerable to opportunistic infections as evidenced in most solid organ- transplants (e.g. 
kidneys, liver, and pancreas) or cancer patients [40]. In this population of 
immunocompromised patients, the predominately encountered opportunistic infections 
include Mycobacterium tuberculosis, Mycobacterium other than tuberculosis (MOTT), 
Aspergillus sp., Crptococcus neoformans, cytomegalovirus, and/or pneumocystis jirovecii 
pneumonia.  
6. Immunological evaluation of immunosuppression 
Despite the application of various treatment modalities for the control of infection in 
immunocompromised patients, a limited number of methods are available for the 
evaluation of immunosuppression.  Most of the available methods rely on T or B cells 
function as exemplified by lymphocytes activation and proliferation, cytokines production, 
leukocytes count and expression, and specific antibody production.  Although these 
methods are well established in several research studies, only ELISA for antibody and 
cytokine assays and flow cytometry for leukocyte counts and markers expression are 
commonly used in clinical referral laboratories.  However, in routine diagnostic laboratories, 
none of these methods are approached properly. Therefore, there is an urgent need to 
scrutinize the fidelity of these methods in the evaluation of immunosuppression in most 
clinical laboratories.  The rationale is to identify the immunocompetence of the host before 
the institution of any therapeutic intervention [41].  
For routine isolation of lymphocytes and monocytes in anti-coagulant-treated blood, density 
gradient centrifugation [42] is used after lysis of red cells. For the isolation of neutrophils, 
dextran sedimentation is firstly used for the isolation of leukocytes-rich preparation 
followed by density gradient sedimentation in Percoll A. In both settings, the viability of 
leukocytes can be measured by trypan blue exclusion and phenotyping of leukocytes 
preparation can be established by flow cytometry using the commercially available 
monoclonal antibodies against leukocyte surface antigens (CD). HLA typing can be 
conducted similarly. For functional analysis of phagocytic cells (macrophages or 
neutrophils), limited methods are used including phagocytosis (ingestion), opsonisation 
(enhanced attachment), and chemotaxis (directed cell motility).   
7. Conclusions   
Immunosuppression is a sword of two edges; while it is beneficial when intentionally 
instituted to maintain the life in solid organ-transplants or cancer patients, it is perilous in 
patients with primary immunodeficiency diseases, patients with HIV infection, and/or 
patients with multiple organ failure. Therefore, the mediating factors must be scrutinized, 
the leukocyte counts and function must be stated and the pros and cons of an 
immunosuppressant medicine must be thoroughly evaluated before being prescribed.  
8. Acknowledgements 
The authors acknowledged the support of King Faisal Specialist Hospital and Research 
Centre, the King Saud University, and the King Abdulaziz City for Science and Technology 
for the financial support.   
www.intechopen.com
 
Immunosuppression – Role in Health and Diseases 
 
222 
9. References 
[1] Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., and Karin, M., (1995).  
Immunosuppression by glucocorticoids: inhibition of NF-kǃ activation through 
induction of I kappa biosynthesis, Science, 270: 286-290. 
[2] Delves, P.J., and Roitt, I.M., (2000). The immune system. First of two parts, N. Engl. J. 
Med. 343: 37-49. 
[3] Delves, P.J., and Roitt, I.M., (2000). The immune system. Second of two parts, N. Engl. J. 
Med. 343: 108-117. 
[4] Figueroa, J.E., and Densen, P., (1991). Infectious diseases associated with complement 
deficiencies, Clin. Microbiol. Rev., 4: 359-395. 
[5]  Gaspar, H.B., Sharifi, R., Gilmour, K.C., and Thrasher, A.J., (2002). X-linked 
lymphoproliferative disease: clinical, diagnosis and molecular prospective, Br. J. 
Haematol. 119: 585-595. 
[6] Haskó, G., Deitch, E.A., Szabó, C., Németh, Z.H., and Vizi, E.S., (2002). Adenosine: a 
potential mediator of immunosuppression in multiple organ failure, Curr. Opin. 
Pharmacol. 2: 440-444.  
[7] Douek, D.C., Brenchley, J.M., Betts, M.R., Ambrozak, D.R., Hill, B.J., Okamoto, Y., 
Casazza, J.P., Kuruppu, J., Kuntsman, K., Wolinsky, K., Grossman, Z., Dybul, M., 
Oxenius, A., Price, D.A., Connors, M., and Koup, R.A., (2002). HIV preferentially 
infects HIV-specific CD4+ T cells, Nature, 417: 95-98.  
[8] Uchiyama, T., (1997). Human T cell leukemia virus type 1(HTLV-1) and human diseases, 
Ann. Rev. Immunol. 15: 15-37. 
[9] Yamano, Y., Cohen, C.J., Takenouchi, N., Yao, K., Tomaru, U., Li, H-C., Reiter, Y., and 
Jacobson, S., (2004). Increased expression of human T lymphocyte virus type 1 
(HTLV-1) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 
complexes on CD4+ CD25+ T cells detected by peptide-specific, major 
histocompatibility complex-restricted antibodies in patients with HTLV-1-
associated neurologic disease, J. Exp. Med. 199: 1367-1377. 
[10] Yamano, Y., Nagai, M., Brennan, M., Mora, C.A., Soldan, S.S., Tomaru, U., Takenouchi, 
N., Izumo, S., Osame, M., and Jacobson, S., (2002). Correlation of human T-cell 
lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific 
CD8 (+) T cells, and disease severity in HTLV-1-associated myelopathy 
(HAM/TSP), Blood. 99: 88-94.  
[11] Faulkner, G.C., Krajewski, A.S., and Crawford, D.H., (2000). The ins and outs of EBV 
infection, Trends Microbiol. 8:185-189. 
[12] Neil, J.C., Fulton, R., Rigby, M., and Stewart, M., (1991). Feline leukemia virus: 
Generation of pathogenic and oncogenic variants, Curr. Top. Microbiol. Immunol. 
171: 67-94. 
[13] Gillet, N., Florins, A., Boxus, M., Burteau, C., Nigro, A., Vandermeers, F., Balon, H., 
Bouzar, A-B., Defoiche, J., Burny, A., Reichert, M., Kettmann, R., and Willems, L., 
(2007). Mechanisms of leukemogenesis induced by bovine leukemia virus: 
prospects for novel anti-retroviral therapies in human, Retrovirol. 4: 18. 
[14] Calnek, B.W., (2001). Pathogenesis of Marex’s disease virus infection, In: Kanji Hirai 
(Ed.), Marek’s Disease, Springer-Verlag, Berlin Heidelberg, Germany, p. 25-49.   
[15] Van den Berg, T.P., (2000). Acute infectious bursal disease in poultry: a review, Avian 
Pathol. 29: 175-194. 
www.intechopen.com
 
Microbial Immunosuppression 
 
223 
[16] Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z., 
Bornstein, E., Lambotte, O., Altman, D., Blazar, B.R., Rodriguez, B., Teixeira-
Johnson, L., Landay, A., Martin, J.N., Hecht, F.M., Picker, L.J., Lederman, M.M., 
Deeks, S.G., and Douek, D.C., (2006). Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection, Nat Med. 12: 1365-1371. 
[17] Ho, D.D., Moudgil, T., and Alam, M., (1989). Quantitation of human immunodeficiency 
virus type 1 in the blood of infected persons, N. Engl. J. Med., 321: 1621-1625. 
[18] Lyerly, H.K., Matthews, T.J., Langlois, A.J., Bolognesi, D.P., and Weinhold, K.J., (1987). 
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 
determinants on normal lymphocytes and expressed by infected cells serves as 
target for immune attack, Proc. Natl. Acad. Sci. USA, 84: 4601-4605. 
[19] Trautmann, L., Janbazian, L., Chomont, N., Said, E., Gimmig, S., Bessette, B., Boulassel, 
M-R, Delwart, E., Sepulveda, H., Balderas, R.S., Routy, J-P., Haddad, E.K., and 
Sekaly, R-P., (2006). Upregulation of PD-1 expression on HIV-specific CD8+ T cells 
leads to reversible immune dysfunction, Nat. Med. 12: 1198- 1202. 
[20] French, M.A., Price, P., and Stone, S.F., (2004). Immune restoration disease after 
antiretroviral therapy, AIDS.18:1615-1627.  
[21] Cheng, V.C., Yuen, K.Y., Chan, W.M., Wong, S.S., Ma, E.S., and Chan, R.M., (2000). 
Immunerestitution disease involving the innate and adaptive response, Clin. Infect. 
Dis. 30: 882-892. 
[22] Choi, Y., Townend, J., Vincent, T., Zaidi, I., Sarge-Njie, R., Jaye, A., and Clifford, D.B., 
(2011). Neurologic manifestations of human immunodeficiency virus-2: dementia, 
myelopathy, and neuropathy in West Africa, J. Neurovirol., 17: 166-175. 
[23]Costello, D.J., Gonzalez, R.G., Frosch, M.P., (2011). Case 18-2011: A 35-year-old HIV-
positive woman with headache and altered mental status, N. Engl. J. Med.364: 
2343-2352.  
[24] Guihot, A., Dupin, N., Marcelin, A.G., Gorin, I., Bedin, A-S., Bossi, P., Galicier, L., 
Oksenhendler, E., Autran, B., and Carcelain, C., (2006), Low T cell responses to 
human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma, J. 
Infect. Dis. 194: 1078-1088. 
 [25] Johnston, M.I., and Fauci, A.S., (2008). An HIV vaccine—Challenges and Prospects, N. 
Engl. J. Med. 359: 888-890. 
[26] Calender, A., Billaud, M., Aubry, J-P., Banchereau, J., Vuillaume, M., and Lenoir, G., 
(1987). Epstein-Barr virus (EBV) induces expression of B-cell activation markers on 
in vitro infection of EBV-negative B-lymphoma cells, Proc. Natl. Acad. Sci. USA, 84: 
8060-8064.  
[27] Rickinson, A.B., and Moss, D.J., (1997). Human cytotoxic T lymphocyte responses to 
Epstein-Barr virus infection, Ann. Rev. Immunol. 15: 405-431. 
[28] Deretic, V., Singh, S., Master, S., Harris, J., Roberts, E., Kyei, G., Davis, A., de Haro, S., 
Naylor, J., Lee, H-H., Vergne, I., (2006). Mycobacterium tuberculosis inhibition of 
phagolysosome biogenesis and autophagy as a host defence mechanism, Cellular 
Microbiol. 8: 719-727.  
[29] Sonesson, A., Öqvist, B., Hagstam, P., Björkman-Burtscher, I.M., Miörner, H., and 
Petersson, A.C., (2004).  An immunocompromised patient with systemic vasculitis 
suffering from cerebral abscesses due to Nocardia farcinica identified by 16S rRNA 
gene universal PCR, Nephrol. Dial. Transplant. 19: 2896-2900. 
www.intechopen.com
 
Immunosuppression – Role in Health and Diseases 
 
224 
[30] Elfaki, M.G., and Al-Hokail, A.A., (2009).  Transforming growth factor ǃ production 
correlates with depressed lymphocytes function in humans with brucellosis. 
Microbes Infect, 11: 1089-1096. 
[31] Toosi, Z., Gogate, P., Shiratsuchi, H., Young, T., and Ellner, J. J., (1995). Enhanced 
production of TGF-ǃ by blood monocytes from patients with active tuberculosis 
and presence of TGF-ǃ in tuberculous granulomatous lung lesions, J. Immunol. 
154:465-473. 
[32] Eisenstein, T.K., (2001). Implications of Salmonella-induced nitric oxide (NO) for host   
defense and vaccines: NO, an antimicrobial, antitumor, immunosuppressive and 
immunoregulatory molecule, Microbes Infect., 3: 1223-1231. 
[33] Kurita-Ochiai, T., and Ochiai, K., (1996). Immunosuppressive factor from Actinobacillus  
actinomycetemcomitans down regulates cytokine production, Infect. Immun., 64: 50-
54. 
[34] Mariotti, S., Teloni, R., Iona, E., Fattorini, L., Romagnoli, G., Gagliardi, M.C., Orefici, G., 
and Nisini, R., (2004). Mycobacterium tuberculosis diverts alpha interferon-induced 
monocyte differentiation from dendritic cells into immunoprivileged macrophage-
like host cells, Infect. Immun.72: 4385-4392. 
[35] Vergne, I., Chua, J., Lee, H-H., Lucas, M., Belisle, J., and Deretic, V., (2005). Mechanism 
of phagolysosome biogenesis block by viable Mycobacterium tuberculosis, PNAS. 
102: 4033-4038. 
[36] Schlesinger, L.S., Azad, A.K., Torrelles, J.B., Roberts, E., Vergne, I., and Deretic, V., 
(2008). Determinants of phagocytosis, phagosome biogenesis and autophagy for 
Mycobacterium tuberculosis, In: Stefan H.E. Kaufmann, Warwick J. Britton (Eds), 
Handbook of Tuberculosis: Immunology and Cell Biology, Wiley-VCH Verlag 
GmbH & Co. KGaA, Weinheim, Germany, p. 1-22. 
[37]Brander, C., Suscovich, T., Lee, Y., Nguyen, P.T., O’Conner, P., Seebach, J., Jones, N.G., 
van Gorder, M., Walker, B. D., and Scadden, D.T., (2000). Impaired CTL recognition 
of cells latently infected with Kaposi’s sarcoma-associated herpes virus, J. Immunol. 
165: 2077-2083. 
[38] Wingard, J.R., Chen, D.Y., Burns, W.H., Fuller, D.J., Braine, H.G., Yeager, A.M., Kaiser, 
H., Burke, P.J., Graham, M.L., and Santos, G.W., (1988). Cytomegalovirus infection 
after autologous bone marrow transplantation with comparison to infection after 
allogeneic bone marrow transplantation, Blood 71: 1432-1437.  
[39] Labro, M-T., (2005). Influence of antibacterial drugs on the immune system, In: Frans P. 
Nijkamp, Michael J. Parnham (Eds.), Principles of Immunopharmacology, 2nd 
edition, Birkhauser Verlag, Basel, Switzerland, p. 407-439.  
[40] Wadhwa, P.D., and Morrison, V.A., (2006). Infectious complications of chronic 
lymphocytic leukemia, Semin. Oncol. 33: 240-249. 
[41] Folds, J.D., and Schmitz, J.L., (2003). Clinical and laboratory assessment of immunity, J. 
Allergy Clin. Immunol. 111(suppl.2):S702-S711. 
[42] Böyum, A., (1968). Isolation of mononuclear cells and granulocytes from human blood, 
Scand. J. Clin. Lab. Invest. Suppl. 97: 77-89. 
www.intechopen.com
Immunosuppression - Role in Health and Diseases
Edited by Dr. Suman Kapur
ISBN 978-953-51-0152-9
Hard cover, 470 pages
Publisher InTech
Published online 24, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
A need for a book on immunology which primarily focuses on the needs of medical and clinical research
students was recognized. This book, "Immunosuppression - Role in Health and Diseases" is relatively short
and contains topics relevant to the understanding of human immune system and its role in health and
diseases. Immunosuppression involves an act that reduces the activation or efficacy of the immune system.
Therapeutic immunosuppression has applications in clinical medicine, ranging from prevention and treatment
of organ/bone marrow transplant rejection, management of autoimmune and inflammatory disorders. It brings
important developments both in the field of molecular mechanisms involved and active therapeutic approaches
employed for immunosuppression in various human disease conditions. There was a need to bring this
information together in a single volume, as much of the recent developments are dispersed throughout
biomedical literature, largely in specialized journals. This book will serve well the practicing physicians,
surgeons and biomedical scientists as it provides an insight into various approaches to immunosuppression
and reviews current developments in each area.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mohamed G. Elfaki, Abdullah A. Al-Hokail and Abdelmageed M. Kambal (2012). Microbial
Immunosuppression, Immunosuppression - Role in Health and Diseases, Dr. Suman Kapur (Ed.), ISBN: 978-
953-51-0152-9, InTech, Available from: http://www.intechopen.com/books/immunosuppression-role-in-health-
and-diseases/microbial-immunosuppression
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
